• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Checkmate Pharmaceuticals Inc.

    2/14/22 11:56:27 AM ET
    $CMPI
    Specialty Chemicals
    Consumer Durables
    Get the next $CMPI alert in real time by email
    SC 13G 1 tm226449d4_sc13g.htm SC 13G

     

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. ________)*

     

    Checkmate Pharamaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 Par Value

    (Title of Class of Securities)

     

    162818108

    (CUSIP Number)

     

    Laura Tse

    3000 Sand Hill Road, Building 2, Suite 110

    Menlo Park, CA 94025, USA

    650-233-0688

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    December 31, 2021

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    þ Rule 13d-1(b)
    ¨  Rule 13d-1(c)
    ¨  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 162818108   13G   Page 2 of 5 Pages

     

             
    1.   NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Decheng Capital Management III (Cayman), LLC
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨
       
    3.   SEC USE ONLY
     
       
    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION
     

     

       

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      5.   SOLE VOTING POWER
     
    1,333,254
      6.   SHARED VOTING POWER
     
    0
      7.   SOLE DISPOSITIVE POWER
     
    1,333,254
      8.   SHARED DISPOSITIVE POWER
     
    0

    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,333,254
       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.16%
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    IA
       

     

     

     

     

    CUSIP No. 162818108   13G   Page 3 of 5 Pages

     

    Item 1.

     

      (a) Name of Issuer

    Checkmate Pharamaceuticals, Inc.

         
      (b) Address of Issuer’s Principal Executive Offices

    245 Main Street, 2nd Floor, Cambridge, MA 02142, USA

         

    Item 2.

     

      (a) Name of Person Filing
    Laura Tse
         
      (b) Address of the Principal Office or, if none, residence
    3000 Sand Hill Road, Building 2, Suite 110, Menlo Park, CA 94025, USA
         
      (c) Citizenship
    U.S.
         
      (d) Title of Class of Securities
    Common Stock, $0.0001 Par Value
         
      (e) CUSIP Number
    162818108
         

    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) þ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

     

     

    CUSIP No. 162818108   13G   Page 4 of 5 Pages

     

    Item 4.  Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. 

             
      (a)   Amount beneficially owned:  1,333,254
             
      (b)   Percent of class:  6.16%
             
      (c)   Number of shares as to which the person has:  
             
          (i) Sole power to vote or to direct the vote 1,333,254
             
          (ii) Shared power to vote or to direct the vote 0
             
          (iii) Sole power to dispose or to direct the disposition of 1,333,254
             
          (iv) Shared power to dispose or to direct the disposition of 0
             

     

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5.  Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following     ¨.

     

    Instruction. Dissolution of a group requires a response to this item.

     

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

     

     None/Not Applicable

     

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

     None/Not Applicable

     

    Item 8.  Identification and Classification of Members of the Group.

     

     None/Not Applicable

     

    Item 9.  Notice of Dissolution of Group.

     

     None/Not Applicable

     

     

     

     

    CUSIP No. 162818108   13G   Page 5 of 5 Pages

     

    Item 10.  Certification.

     

      (a)   The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
           
          By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
           
      (b)   The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):
           
          By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
           

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    2/14/2022

    Date

       
     

    /s/ Laura Tse

    Signature

       
     

    Chief Compliance Officer

    Name/Title

       

     

     

     

    Get the next $CMPI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CMPI

    DatePrice TargetRatingAnalyst
    10/6/2021$7.00Neutral → Buy
    B of A Securities
    More analyst ratings

    $CMPI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Axonis Therapeutics Announces $115 Million Series A Financing

      -- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent

      10/30/24 6:00:00 AM ET
      $AKRO
      $APLS
      $AUPH
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Chemicals
      Consumer Durables
    • venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies

      - venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo

      8/1/24 8:00:00 AM ET
      $AKRO
      $APLS
      $AUPH
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Chemicals
      Consumer Durables
    • Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update

      CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced first quarter 2022 financial results and provided a business update. "We remain focused on the execution of the clinical program for vidutolimod and are delighted with the opportunity to become part of Regeneron, who will help to accelerate the development of vidutolimod as a potential novel treatment for multiple tumor types," said Alan Bash, President and Chief Executive Officer of Checkmate. "This is an excitin

      5/12/22 4:30:00 PM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables

    $CMPI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Checkmate Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)

      6/7/22 4:15:17 PM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables
    • SEC Form SC 13D/A filed by Checkmate Pharmaceuticals Inc. (Amendment)

      SC 13D/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)

      6/7/22 11:39:45 AM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables
    • SEC Form SC 13D/A filed by Checkmate Pharmaceuticals Inc. (Amendment)

      SC 13D/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)

      6/3/22 3:01:59 PM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables

    $CMPI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Powell Michael

      4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

      5/31/22 10:14:50 AM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables
    • SEC Form 4 filed by Flaherty Keith T.

      4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

      5/31/22 10:12:51 AM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables
    • SEC Form 4 filed by Isacoff Oren

      4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

      5/31/22 10:11:23 AM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables

    $CMPI
    Leadership Updates

    Live Leadership Updates

    See more
    • Checkmate Pharmaceuticals Appoints Alan Bash as President and CEO

      CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the appointment of Alan Bash as President and Chief Executive Officer, effective March 1, 2022. Mr. Bash, who will also join the Board of Directors, will succeed Alan Fuhrman, who has served as interim President and Chief Executive Officer since October 2021. Mr. Fuhrman will continue to serve Checkmate as a member of the Board of Directors. "I am very pleased to welcome Alan Bash as President and CEO. With ove

      2/9/22 8:00:00 AM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables
    • Checkmate Pharmaceuticals Strengthens Board of Directors with Appointment of Joy Yan, M.D., Ph.D.

      CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the addition of Joy Yan, M.D., Ph.D. to its Board of Directors ("Board"). "Joy's impressive track record in immuno-oncology focused clinical development will be valuable as we continue to advance vidutolimod toward registration in melanoma and proof of concept in additional indications," commented Alan Fuhrman, Interim CEO and President of Checkmate. "We are pleased to welcome Joy to Checkmate's Board." Dr. Yan

      12/20/21 7:00:00 AM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables
    • Checkmate Pharmaceuticals Announces Key Additions to Executive Management Team

      Robert F. Dolski appointed as Chief Financial Officer Katherine Eade appointed as General Counsel CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the appointment of Robert F. Dolski as Chief Financial Officer. Mr. Dolski brings to Checkmate more than 20 years of diversified management experience as a life sciences financial executive driving the strategy, planning, execution, and financing of private and public biopharmaceutical companies. In addition to Mr

      1/4/21 4:30:00 PM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables

    $CMPI
    SEC Filings

    See more
    • SEC Form 15-12B filed by Checkmate Pharmaceuticals Inc.

      15-12B - Checkmate Pharmaceuticals, Inc. (0001651431) (Filer)

      6/10/22 8:37:08 AM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables
    • SEC Form EFFECT filed by Checkmate Pharmaceuticals Inc.

      EFFECT - Checkmate Pharmaceuticals, Inc. (0001651431) (Filer)

      6/2/22 12:15:14 AM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables
    • SEC Form 25-NSE filed by Checkmate Pharmaceuticals Inc.

      25-NSE - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)

      5/31/22 5:21:06 PM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables

    $CMPI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Checkmate Pharmaceuticals upgraded by B of A Securities with a new price target

      B of A Securities upgraded Checkmate Pharmaceuticals from Neutral to Buy and set a new price target of $7.00

      10/6/21 7:25:42 AM ET
      $CMPI
      Specialty Chemicals
      Consumer Durables